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Abstract
Introduction: Recruitment of the inflammatory cells from blood to the airways in asthma is mediated by adhesive
molecules, e.g. selectins and integrins. The most important integrins in cells trafficking are molecules containing
α4 and β2 subunits. We hypothesized that also α1β1 and α2β1 integrins (both found by us on blood eosinophils
of asthmatic subjects) are important in asthma pathogenesis.
Aim: To assess the expression of selected very late antigen (VLA) subunits (α1, α2, α4 and β1) on blood CD4 and CD8
T lymphocytes from stable atopic asthmatic patients. 
Material and methods: The study was conducted on 25 adult atopic asthmatics (mild to moderate persistent asth-
ma in a stable clinical condition) and 17 matched healthy controls using flow cytometry. 
Results: Expression of α4 and β1 on CD4 T cells was significantly higher in asthma than in controls. The α1 subunit
was absent from blood lymphocytes. The α2 chain hardly detected on lymphocytes from healthy subjects was dis-
tinctively present in asthmatics. Surprisingly, in subjects suffering from asthma for longer than 4 years (n = 15),
the overexpression of α2, α4 and β1 was observed on both: CD4 and CD8 T cells. 
Conclusions: Expression of selected VLA subunits on blood T cells may depend on asthma duration. The biological
role of α2β1 integrin in asthma is unknown, but as it was described as a stimulator of collagen accumulation in
the airways, α2β1 integrin could be, at least in part, responsible for asthma airway remodelling. 
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Introduction
Bronchial asthma is a chronic, inflammatory disease
of the airways, which due to its frequency, poses an impor-
tant public health problem. It is characterized by reversible
airflow limitation and bronchial hyper-responsiveness;
both leading to the distinct clinical symptoms: chest tight-
ness, cough and breathlessness. Unfortunately, patho-
genesis of asthma is only partially understood. It is asso-
ciated with environmental factors together with variable
inflammatory cell activation. T helper lymphocytes, in par-
ticular Th2 subtype are likely to be pivotal in directing
the disease development and progression and leading to
the eosinophilic airway inflammation. Activated Th2 cells
are present in the airways even when the disease is qui-
escent. Adoptive transfer of Ag-primed T cells in naïve ani-
mals induces eosinophilia, bronchial hyper-responsiveness
and late airway response [1]. Eosinophils are considered
the major effector cells in asthmatic airway inflammation.
Interestingly, anti-IL-5 antibodies, able to reduce blood and
lung eosinophilia, did not change asthma severity [2]. Some
believe that non-eosinophilic inflammation and airway
remodelling contribute to the persistence and progression
of the disease, despite anti-inflammatory therapy [3]. 
Recruitment of the engaged cells is crucial to
the development of the inflammatory reaction. This
process is mediated by adhesive molecules, such as gly-
coproteins, selectins and integrins [4]. Integrins are a fam-
ily of heterodimeric glycoproteins composed of non-cova-
lently associated α and β subunits. They are present on
almost all viable cells and regulate between cell and cell
to matrix interactions [5]. Also leukocyte migration into
Postępy Dermatologii i Alergologii XXIX; 2012/5338
the lung is mediated by integrins, in particular those con-
taining α4 (α4β1 and α4β7) and β2 subunits (LFA-1 – inte-
grin αLβ2 – CD11a/CD18; Mac-1 – integrin αMβ2 –
CD11b/CD18, integrin αXβ2 – CD11c/CD18 and integrin
αDβ2 – CD11d/CD18). All those integrins have been inten-
sively studied in inflammatory diseases, like asthma, and
considered a possible therapeutic target [6, 7]. We have
previously suggested that collagen integrin receptors: α1β1
and α2β1, both found on peripheral blood eosinophils
of asthmatic subjects, may be involved in asthma patho-
genesis [8]. The α1β1 integrin belongs to the β1 inte-
grin family (also called very late antigen-1 – VLA-1). It is
a specific receptor for collagen IV, the main component
of the small vessel basement membrane [9]. Very late
antigen-1  is expressed inter alia on fibroblasts, mes-
enchymal and epithelial cells, macrophages and, NK and
T lymphocytes after their activation [10]. It plays a role in
angiogenesis, metastasis, cell migration and cytokine
secretion. Anti-inflammatory effects of the VLA-1 antag-
onists were observed in animal models of arthritis [11],
colitis [12], allergen-induced bronchoconstriction [13] and
glomerulonephritis [14].
The α2β1 integrin (VLA-2) is a collagen I receptor. Its
main function is connected with haemostasis. VLA-2 also
promotes neoplasm invasion [15]. But collagen I is also an
important component of extracellular matrix of the lungs
and VLA-2 was described as a stimulator of collagen and
fibronectin accumulation in the airways – crucial element
of airway remodelling [16, 17]. 
Aim
The aim of this study was to analyse the expression
of collagen receptors: integrins α1β1 and α2β1 on periph-
eral blood CD4 and CD8 T lymphocytes in subjects with
chronic clinically stable atopic asthma.
Material and methods
The study was conducted on 25 adult atopic asth-
matics and 17 healthy controls. All asthma patients were
in a stable clinical condition with mild (n = 15) to moder-
ate (n = 10) persistent asthma, according to the GINA
guidelines [18]. Their atopic status was confirmed by
a positive skin testing for at least one standard inhaled
allergen (Allergopharma, Germany). Most of them had
a good or partially controlled asthma (GINA 2006) and
were treated with a medium dose of inhaled glucocorti-
costeroids and long-acting β2-agonists. Smokers and
patients suffering from heart failure, diabetes mellitus,
renal or hepatic diseases, as well as other chronic diseases
were excluded from the study. The control group consist-
ed of non-atopic and non-smoking volunteers, without
any chronic illness. Our study was approved by the Jagiel-
lonian University Ethical Committee and all subjects gave
informed consent to participate in this study.
Expression of α1, α2, α4 and β1 integrin subunits on
CD4 and CD8 peripheral blood T lymphocytes was
analysed by flow cytometry (Epics XL, Beckman Coulter
International, Nyon, Switzerland) and expressed as Medi-
an Fluorescence Intensity (MFI). 
A 100 µl samples of venous peripheral blood taken on
EDTA was incubated with monoclonal antibodies (mAbs)
in a concentration of 10 µl/100 µl using threefold staining: 
1) PerCP-conjugated mouse anti human-CD3 mAb for lym-
phocyte T detection; 
2) FITC-conjugated mouse anti human-CD4 or CD8 mAb; 
3) PE-conjugated mouse anti human – CD49a (anti-α1), or
CD49b (anti-α2), or CD49d (anti-α4), or CD29 (anti-β1)
mAbs. 
All monoclonal antibodies were purchased from BD
Pharmingen, (San Diego, CA, USA). The isotypic control
was performed using mouse IgG antibody against keyhole
limpet hemocyanin antigen (KLH), purchased from Becton
Dickinson Biosciences (San Jose, CA, USA) and PE, FITC 
and PerCP – labelled goat anti-mouse IgG (1 µg/100 µl;
Jackson Immuno Research Laboratories, West Grove, PA,
USA). Serum concentration of IgE and eosinophil cation-
ic protein (ECP) was measured using UniCAP System,
Pharmacia, Sweden.
Statistical analysis
Normally distributed results were reported in tables
as a mean ± standard deviation (SD). Values, which were
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Table 1. Clinical and laboratory characteristics of the subjects studied
Variable Asthmatics (n = 25) Healthy controls (n = 17) Difference
Male/female ratio 9/16 6/11 NS
Age, mean ± SD [years] 42 ±14.5 33 ±12 NS
Duration of asthma, mean (min-max) [years] 11 (1-35)
FEV1 ± SD (% of predicted) 88 ±18
Blood eosinophilia, median (interquartile range) [/mm3] 177 (134) 82.8 (57.5) p < 0.05
Total IgE, median (interquartile range) [IU/l] 157 (216) 17.2 (33) p < 0.05
Serum ECP, median (interquartile range) [UG/l] 18 (10.1) 7.5 (4) p < 0.05
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Table 2. Median Fluorescence Intensity (MFI) of analysed integrin subunits in all subjects studied (results shown as a median
and interquartile range)
Subunits Asthma Control Difference Asthma Control Difference
analyzed CD4 T cells CD4 T cells CD8 T cells CD8 T cells 
α1 1.98 (0.31) 1.92 (0.8) NS 2.07 (0.26) 2.05 (0.41) NS
α2 4.24 (2.18) 3.56 (1.05) NS 3.44 (2.1) 2.69 (1.65) NS
α4 10.5 (4.54) 8.14 (3.19) 0.02 15.9 (4.6) 12.8 (4.1) NS
β1 15.6 (5.3) 11.7 (6.65) 0.0004 14.6 (6.3) 11.2 (7.3) NS
Figure 1. Example of the fluorescence pattern of studied integrin subunits in an asthma subject (bold line) and healthy
control (thin line with shape shadow)
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not normally distributed, were presented in tables as
a median with interquartile range and in figures as
a median with standard error of median. Comparison
between experimental groups were tested using Mann-
Whitney U test, whilst relationships were tested using
Spearman Rank Correlations. Two-sided 5% level of sig-
nificance was used. All statistical testing was performed
by Statistica StatSoft (Tulsa, OK, USA) software.
Results
The summary of the results is shown in Tables 1, 2 and
Figures 1 and 2. The groups studied were similar as 
to age and sex. Patients had significantly higher blood
eosinophilia and serum levels of ECP and IgE (Table 1).
As shown in Table 2 and Figure 1, the expression
of both α4 and β1 chains was significantly higher in asth-
ma subjects as compared to controls, but only for CD4 
T cells (p = 0.02 and p = 0.0004, respectively). The α1 sub-
unit was absent in almost all subjects studied (only a few
asthma patients had detectable fluorescence for α1 chain).
On the other hand, α2 subunit was found on blood T lym-
phocytes of both studied groups, but its expression was
low, slightly higher in asthma, particularly on CD4 T cells
(the difference was not significant). 
Surprisingly, in subjects suffering from asthma for
longer than 4 years (n = 15) not only α4 and β1, but also
α2 chain was overexpressed on CD4 T cells, with α2 and
α4 overexpression on CD8 (Figure 2). 
Similarly, a significantly higher expression of α2, 
α4 and β1 was observed on CD4 T cells in a group
of patients with at least one asthma exacerbation dur-
ing the last 12 months, in comparison to healthy subjects 
(n = 9, p = 0.04; p = 0.04; p = 0.001, respectively). 
No correlation was found between the chain expres-
sion, dose of inhaled steroids, IgE level, ECP or eosino -
phils count. A positive correlation was found for blood
eosinophilia and ECP concentration (p = 0.009) only.
Discussion 
An increased expression of α4 and β1 subunits on
blood CD4 T lymphocytes in clinically stable, asympto-
matic asthmatics confirmed pre-activation and readiness
for migration of these cells to the inflammatory site. How-
ever, in our studies, both chains were also detected on
blood lymphocytes in healthy individuals and on periph-
eral blood eosinophils in healthy and asthmatic subjects
[8]. Both are intensively studied as a possible therapeu-
tic target in many inflammatory diseases, such as asth-
ma [6, 7, 19]. Integrins containing α4 and β1 subunits are
important or even critical for immunity and body health
control. For this reason blockade of α4 and β1 could be
hazardous and lead to unexpected outcomes. Natal-
izumab, a humanized IgG4 anti-α4-integrin monoclonal
antibody inhibits both: α4β7/mucosal addressin-cell adhe-
sion molecule-1 (MadCAM-1) and α4β1/vascular-cell adhe-
sion molecule-1 (VCAM-1) interactions. Administration
of natalizumab was shown to be highly effective in
patients with multiple sclerosis and Crohn’s disease 
[20, 21]. Unfortunately, it has been also implicated in some
cases of progressive multifocal leukoencephalopathy, due
to JC virus activation as a consequence of severe immuno-
suppression [22]. It seems that for therapeutic purposes,
a target more selective and specific to a particular dis-
ease could be safer. In our study, an expression of α2 sub-
unit on blood lymphocytes was low, but increased in
patients suffering from asthma for longer than 4 years,
even despite chronic anti-inflammatory therapy and lack
of clinical symptoms. Our findings were not in a clear rela-
tionship with the type of treatment and current severity
of symptoms. The biological function of α2β1 in asthma
is still unknown. An increased expression of this integrin
was found by others on blood lymphocytes but only dur-
ing severe exacerbation of asthma [23, 24]. We also found
a higher expression of α2 subunit on CD4 T cells in
patients, who had at least one exacerbation during
the last year of the patient’s observation. We speculate
Figure 2. Median Fluorescence Intensity (MFI) of studied integrin subunits in a group of patients suffering from asthma
for longer than 4 years (n = 15) in comparison to healthy controls (n = 17) (results shown as a median and standard error
of median)
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that integrin α2β1 is not involved in lymphocyte transmi-
gration but rather acts on turnover of the extracellular
matrix, as a stimulator of remodelling. The α2β1 integrin
has been described previously as a stimulator of collagen
and fibronectin accumulation in the airways [25]. Fibrob-
lasts initiate collagen degradation through this integrin
[26], whereas α1β1 integrin is important in collagen fibrils
organization and in feedback inhibition of collagen I syn-
thesis [27]. Our findings indicate that an expression of α2
on T cells is much lower than this observed for e.g. α4 and
β1. In our preliminary experiments with transmigration
of eosinophil and lymphocyte through human extracel-
lular matrix and collagen I coated inserts, blockade of α2
integrin subunit by functional active mAbs, as well as 
VP-12 (viper venom lectin – selective inhibitor of α2β1 inte-
grin) had no impact on lymphocyte transmigration, but
decreased migration of eosinophils (data not published). 
Till now airway remodelling could not be reversed.
Current recommended asthma treatment is partially suc-
cessful in limiting allergic inflammation but does not
specifically address the remodelling process. Despite
aggressive treatment asthma often progresses [28]. Clin-
ical studies suggest that use of inhaled glucocorticoids
before the age of 2 has no effect on asthma 8 years lat-
er [29]. Experimental asthma therapy with imatinib (tyro-
sine kinase inhibitor) can prevent airway inflammation
and remodelling in the murine model by inhibition of
collagen deposition [30, 31]. The mode of such action is
unknown, but could be connected to interaction with inte-
grin collagen receptors. Integrin-linked cytoplasmic kinase
can activate and regulate smooth muscle contraction
directly by myosin phosphorylation and indirectly by
myosin light-chain phosphatise inhibition [32]. There are
only five known collagen integrin receptors: α1β1, α2β1,
α3β1, α10β1 and α11β1 [33]. We studied two of them, but it
is tempting to speculate that integrin collagen receptors
could become a new therapeutic target in treatment
of asthmatic airway remodelling.
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